Literature DB >> 2434162

Prognostic value of response after three MOPP cycles in Hodgkin's disease--stage III and IV.

M Monconduit, H Tilly, J F Menard, R Le Fur, A Barbot, H Piguet.   

Abstract

Sixty-eight patients with Hodgkin's disease stage III and IV were evaluated after three out of six MOPP cycles. At that time, 46 (68%) were classified as early responders and 22 as slow responders. The criteria of response were: disappearance of B symptoms, decrease in the size of the largest lymph nodes (by more than 50%) and significant reduction (more than 20%) of mediastinal enlargement. Out of 43 early responders, 38 were in complete remission after six MOPP cycles and only five out of 22 slow responders. Such an early response is only related to the absence of B symptoms at the time of diagnosis (p less than 0.05). The survival curves of early responders and slow responders were significantly different (p less than 0.02). A rapid erythrocyte sedimentation rate (ESR) (greater than 50 mm) was the most frequently abnormal sign found in the group not responding after three MOPP cycles (p less than 0.0001). Such a significant prognostic value of early response is observed for stage III but not for stage IV patients. We conclude that early clinical response after three MOPP cycles is a good prognostic factor which must be kept in mind in the formulation of the therapeutic regimen for Hodgkin's disease stage III and IV.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2434162     DOI: 10.1007/bf00320373

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  17 in total

1.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

2.  Early response to chemotherapy as a prognostic factor in Hodgkin's disease.

Authors:  M Kuentz; F Reyes; B Brun; J P Lebourgeois; P Bierling; J P Farcet; J P Vernant; M Imbert; M Le Bezu; H Rochant; B Dreyfus
Journal:  Cancer       Date:  1983-09-01       Impact factor: 6.860

Review 3.  [Treatment of Hodgkin's disease].

Authors:  J M Andrieu
Journal:  Ann Med Interne (Paris)       Date:  1982

4.  Acute myeloid leukemia following treatment of Hodgkin's disease: a review.

Authors:  H W Grünwald; F Rosner
Journal:  Cancer       Date:  1982-08-15       Impact factor: 6.860

5.  [Stage III and VI Hodgkin's disease. Success and failure of therapeutic protocol H2 65 (author's transl)].

Authors:  C Jacquillat; G Auclerc; J P Desprez-Curely; M F Auclerc; J M Andrieu; M Weil; M Boiron; J Bernard
Journal:  Nouv Presse Med       Date:  1979 Jul 14-28

6.  A comparative study of a BCNU containing 4-drug program versus MOPP versus 3-drug combinations in advanced Hodgkin's disease: a cooperative study by the Cancer and Leukemia Group B.

Authors:  N I Nissen; T F Pajak; O Glidewell; J Pedersen-Bjergaard; L Stutzman; G Falkson; J Cuttner; J Blom; L Leone; A Sawitsky; M Coleman; F Haurani; C L Spurr; J B Harley; B Seligman; C Cornell; P Henry; H J Senn; K Brunner; G Martz; P Maurice; A Bank; L Shapiro; G W James; J F Holland
Journal:  Cancer       Date:  1979-01       Impact factor: 6.860

7.  Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.

Authors:  G Bonadonna; A Santoro; V Bonfante; P Valagussa
Journal:  Cancer Treat Rep       Date:  1982-04

8.  Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine.

Authors:  L H Einhorn; S D Williams; E E Stevens; W H Bond; L Chenoweth
Journal:  Cancer       Date:  1983-04-15       Impact factor: 6.860

9.  Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy.

Authors:  R C Young; G P Canellos; B A Chabner; S M Hubbard; V T DeVita
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

10.  Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute.

Authors:  V T DeVita; R M Simon; S M Hubbard; R C Young; C W Berard; J H Moxley; E Frei; P P Carbone; G P Canellos
Journal:  Ann Intern Med       Date:  1980-05       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.